Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 23824675)

1.

Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Cottrell ML, Hadzic T, Kashuba AD.

Clin Pharmacokinet. 2013 Nov;52(11):981-94. doi: 10.1007/s40262-013-0093-2. Review.

2.

Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.

Rathbun RC, Lockhart SM, Miller MM, Liedtke MD.

Ann Pharmacother. 2014 Mar;48(3):395-403. doi: 10.1177/1060028013513558. Epub 2013 Nov 19. Review.

PMID:
24259658
3.

Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.

Shah BM, Schafer JJ, Desimone JA Jr.

Pharmacotherapy. 2014 May;34(5):506-20. doi: 10.1002/phar.1386. Epub 2013 Dec 18. Review. Erratum in: Pharmacotherapy. 2014 Jun;34(6):667.

PMID:
24347095
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

PMID:
23830355
6.

Pharmacology of HIV integrase inhibitors.

Adams JL, Greener BN, Kashuba AD.

Curr Opin HIV AIDS. 2012 Sep;7(5):390-400. doi: 10.1097/COH.0b013e328356e91c. Review.

7.

Dolutegravir: clinical efficacy and role in HIV therapy.

Fantauzzi A, Mezzaroma I.

Ther Adv Chronic Dis. 2014 Jul;5(4):164-77. doi: 10.1177/2040622314530461. Review.

8.

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

DeAnda F, Hightower KE, Nolte RT, Hattori K, Yoshinaga T, Kawasuji T, Underwood MR.

PLoS One. 2013 Oct 16;8(10):e77448. doi: 10.1371/journal.pone.0077448. eCollection 2013.

9.

Dolutegravir for the treatment of adult patients with HIV-1 infection.

Wu G, Abraham T, Saad N.

Expert Rev Anti Infect Ther. 2014 May;12(5):535-44. doi: 10.1586/14787210.2014.907525. Epub 2014 Apr 2. Review.

PMID:
24694091
10.

Tolerability of HIV integrase inhibitors.

Lee FJ, Carr A.

Curr Opin HIV AIDS. 2012 Sep;7(5):422-8. doi: 10.1097/COH.0b013e328356682a. Review.

PMID:
22886031
11.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group.

Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.

PMID:
23306000
12.

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S.

Lancet Infect Dis. 2012 Feb;12(2):111-8. doi: 10.1016/S1473-3099(11)70290-0. Epub 2011 Oct 20.

PMID:
22018760
13.

Potential benefit of dolutegravir once daily: efficacy and safety.

Fantauzzi A, Turriziani O, Mezzaroma I.

HIV AIDS (Auckl). 2013;5:29-40. doi: 10.2147/HIV.S27765. Epub 2013 Feb 7.

14.

Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.

Osterholzer DA, Goldman M.

Clin Infect Dis. 2014 Jul 15;59(2):265-71. doi: 10.1093/cid/ciu221. Epub 2014 Apr 9.

PMID:
24723281
15.

Update on raltegravir and the development of new integrase strand transfer inhibitors.

Shamroe CL, Bookstaver PB, Rokas KE, Weissman SB.

South Med J. 2012 Jul;105(7):370-8. doi: 10.1097/SMJ.0b013e318258c847. Review.

PMID:
22766666
16.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S; extended SPRING-2 Study Group.

Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473-3099(13)70257-3. Epub 2013 Sep 25.

PMID:
24074642
17.

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.

Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min SS, Goljer I, Culp A, Piscitelli SC, Savina PM.

Antimicrob Agents Chemother. 2013 Aug;57(8):3536-46. doi: 10.1128/AAC.00292-13. Epub 2013 May 13.

18.

Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection.

Temesgen Z, Talwani R, Rizza SA.

Drugs Today (Barc). 2014 Jan;50(1):7-14. doi: 10.1358/dot.2014.50.1.2097790.

PMID:
24524102
19.
20.

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M.

J Antimicrob Chemother. 2013 Nov;68(11):2525-32. doi: 10.1093/jac/dkt220. Epub 2013 Jun 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk